Download PDF
Geburtshilfe Frauenheilkd 2009; 69(9): 807-833
DOI: 10.1055/s-0029-1186007
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Borderline-Tumoren des Ovars – eine systematische Übersicht

Borderline Tumors of the Ovary – A Systematic ReviewA. du Bois1 , N. Ewald-Riegler1 , O. du Bois1 , P. Harter1
  • 1Klinik für Gynäkologie & Gynäkologische Onkologie, Dr. Horst Schmidt Klinik Wiesbaden
Further Information

Publication History

eingereicht 6.5.2009

akzeptiert 29.6.2009

Publication Date:
21 September 2009 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Für diese systematische Übersicht wurden Arbeiten in deutscher und englischer Sprache über eine MEDLINE-Suche identifiziert. Zusätzlich wurden die Literaturangaben der Reviews durchgesehen und so weitere Arbeiten identifiziert. Daraus wurden etwa 200 Publikationen für die weitere Bearbeitung nach Screening des Titels und des Abstracts ausgewählt. Die Daten wurden mittels eines standardisierten Fragebogens extrahiert und folgenden Fragestellungen zugeordnet: Epidemiologie und Risikofaktoren, Pathogenese und Prognosefaktoren, Klinik und Therapie sowie onkologischer und reproduktionsmedizinischer Verlauf. Diese Übersicht stellt die derzeit aktuellste und kompletteste Übersicht zu den Borderline-Tumoren dar und bietet die Grundlage für Therapieberatung und Entscheidung in der Behandlung betroffener Patientinnen.

Abstract

This systematic review is based on a MEDLINE search including English and German papers. In addition, hand search of all reviews was performed and articles were added. Overall, about 200 articles were identified and screened. Data extraction was performed by a standardized questionnaire and data were sorted according to predefined points of interest: epidemiology and risk factors, clinics and therapy, and oncologic long-term outcome and reproductive outcome. This review presents the most comprehensive data collection currently available and may provide a basis for patient counselling.

Schlüsselwörter

Borderline‐Tumor - low malignant potential - Prognosefaktoren - Outcome

Key words

borderline tumors - low malignant potential - prognostic factors - outcome

Literatur

  • 1 Taylor Jr. H C. Malignant and semimalignant tumors of the ovary.  Surg Gynecol Obstet. 1929;  48 204-230
    PubMedGoogle Scholar
  • 2 Seidman J D, Soslow R A, Vang R et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images.  Hum Pathol. 2004;  35 918-933
    CrossrefPubMedGoogle Scholar
  • 3 Bell D A, Longacre T A, Prat J et al. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.  Hum Pathol. 2004;  35 934-948
    CrossrefPubMedGoogle Scholar
  • 4 Silverberg S G, Bell D A, Kurman R J et al. Borderline ovarian tumors: key points and workshop summary.  Hum Pathol. 2004;  35 910-917
    CrossrefPubMedGoogle Scholar
  • 5 Seidman J D, Kurman R J. Ovarian serous borderline tumors: A critical review of the literature with emphasis on prognostic indicators.  Hum Pathol. 2000;  31 539-557
    CrossrefPubMedGoogle Scholar
  • 6 Bell D A, Scully R E. Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases.  Human Pathol. 1990;  21 397-403
    CrossrefPubMedGoogle Scholar
  • 7 Sherman M E, Mink P J, Curtis R et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: A population-based Analysis.  Cancer. 2004;  100 1045-1052
    CrossrefPubMedGoogle Scholar
  • 8 Cusido M, Balaguero L, Hernandez G et al. Results of the national survey of borderline ovarian tumors in Spain.  Gynecol Oncol. 2007;  104 617-622
    CrossrefPubMedGoogle Scholar
  • 9 Akeson M, Zetterqvist B M, Dahllops K et al. Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period.  Int J Gynecol Cancer. 2008;  18 453-459
    CrossrefPubMedGoogle Scholar
  • 10 Kaern J, Tropé C G, Abeler V M. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982.  Cancer. 1993;  71 1810-1820
    CrossrefPubMedGoogle Scholar
  • 11 Park J-Y, Kim D-Y, Kim J-H et al. Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery.  Gynecol Oncol. 2009;  DOI: 10.1016/2008:12034
    PubMedGoogle Scholar
  • 12 Fauvet R, Boccara J, Dufournet C et al. Laparoscopic management of borderline ovarian tumors: results of a French multicenter study.  Ann Oncol. 2005;  16 403-410
    CrossrefPubMedGoogle Scholar
  • 13 Zanetta G, Rota S, Chiari S et al. Behaviour of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study.  J Clin Oncol. 2001;  19 2658-2664
    PubMedGoogle Scholar
  • 14 Trope C, Kaern J, Vergote I B et al. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors.  Gynecol Oncol. 1993;  51 236-243
    CrossrefPubMedGoogle Scholar
  • 15 Longacre T A, McKenney J K, Tazelaar H D et al. Ovarian tumors of low malignant potential (borderline tumors).  Am J Surg Pathol. 2005;  29 707-723
    CrossrefPubMedGoogle Scholar
  • 16 Ren J, Peng Z, Yang K. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors.  Gynecol Oncol. 2008;  110 162-167
    CrossrefPubMedGoogle Scholar
  • 17 Leake J F, Currie J L, Rosenshein N B et al. Long-term follow-up of serous ovarian tumors of low malignant potential.  Gynecol Oncol. 1992;  47 150-158
    CrossrefPubMedGoogle Scholar
  • 18 Morice P, Camatte S, El Hassan J et al. Clinical outcome and fertility after conservative treatment of ovarian borderline tumors.  Fertil Steril. 2001;  75 92-96
    CrossrefPubMedGoogle Scholar
  • 19 De Iaco P, Ferrero A, Rosati F et al. Behaviour of ovarian tumors of low malignant potential treated with conservative surgery.  Eur J Surg Oncol. 2008;  DOI: 10.1016/j.ejso.2008.09.011
    PubMedGoogle Scholar
  • 20 Buttin B, Herzog T J, Powell M A et al. Epithelial ovarian tumors of low malignant potential: The role of microinvasion.  Obstet Gyneccol. 2002;  99 11-17
    PubMedGoogle Scholar
  • 21 Romangnolo C, Gadducci A, Sartori E et al. Management of borderline ovarian tumors: Results of an Italian multicenter study.  Gynecol Oncol. 2006;  101 255-260
    CrossrefPubMedGoogle Scholar
  • 22 Bostwick D G, Tazelaar H D, Ballon S C et al. Ovarian epithelial tumors of borderline malignancy.  Cancer. 1986;  58 2052-2065
    CrossrefPubMedGoogle Scholar
  • 23 Prat J, de Nictolis M. Serous borderline tumors of the ovary: A long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.  Am J Pathol. 2002;  26 1111-1128
    PubMedGoogle Scholar
  • 24 Yokoyama Y, Moriya T, Takano T et al. Clinical outcome and risk factors for recurrence in borderline ovarian tumours.  Br J Cancer. 2006;  94 1586-1591
    PubMedGoogle Scholar
  • 25 Kuoppala T, Heinola M, Aine R et al. Serous and mucinous borderline tumors of the ovary: A clinicopathologic and DNA-ploidy study of 102 cases.  Int J Gynecol Cancer. 1996;  6 302-308
    CrossrefPubMedGoogle Scholar
  • 26 Chambers J T, Merino M J, Kohorn E I et al. Borderline ovarian tumors.  Am J Obstet Gynecol. 1988;  159 1088-1094
    PubMedGoogle Scholar
  • 27 Winter W E, Kucera P R, Rodgers W et al. Surgical staging in patients with tumors of low malignant potential.  Obstet Gynecol. 2002;  100 671-676
    CrossrefPubMedGoogle Scholar
  • 28 Liapis A, Bakalianou K, Iavazzo C et al. A retrospective analysis of borderline ovarian tumors in a Greek university hospital.  Eur J Gynecol Oncol. 2008;  29 383-385
    PubMedGoogle Scholar
  • 29 Gotlieb W H, Flikker S, Davidson B et al. Borderline tumors of the ovary.  Cancer. 1998;  82 141-146
    CrossrefPubMedGoogle Scholar
  • 30 Rice L W, Berkowitz R S, Mark S D et al. Epithelial ovarian tumors of borderline malignancy.  Gynecol Oncol. 1990;  39 195-198
    CrossrefPubMedGoogle Scholar
  • 31 Papadimitriou D S, Martin-Hirsch P, Kitchener H C et al. Recurrent borderline ovarian tumors after conservative management in women wishing to retain their fertility.  Eur J Gynecol Oncol. 1999;  20 94-97
    PubMedGoogle Scholar
  • 32 Kennedy A W, Hart W R. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors): A long follow-up study, including patients with microinvasion, lymph node metastasis and transformation to invasive serous carcinoma.  Cancer. 1996;  78 278-286
    CrossrefPubMedGoogle Scholar
  • 33 Kliman L, Rome R M, Fortune D W. Low malignant potential tumors of the ovary: a study of 76 cases.  Obstet Gynecol. 1986;  68 338-344
    PubMedGoogle Scholar
  • 34 Donnez J, Munschke A, Berliers M et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary.  Fertil Steril. 2003;  79 1216-1221
    CrossrefPubMedGoogle Scholar
  • 35 Tasker M, Langley F A. The outlook for women with borderline epithelial tumours of the ovary.  BJOG. 1985;  92 969-973
    PubMedGoogle Scholar
  • 36 Nakashima N, Nagasaka T, Oiwa N et al. Ovarian epithelial tumors of borderline malignancy in Japan.  Gynecol Oncol. 1990;  38 90-98
    CrossrefPubMedGoogle Scholar
  • 37 Kumpulainen S, Kuoppala T, Leminen A et al. Surgical staging, treatment, and follow-up of borderline tumors in different hospital categories: a prospective nationwide survey in Finland.  Acta Obstet Gynecol. 2007;  86 610-614
    CrossrefPubMedGoogle Scholar
  • 38 Nation J G, Krepart G V. Ovarian carcinoma of low malignant potential: staging and treatment.  Am J Obstet Gynecol. 1986;  154 290-293
    PubMedGoogle Scholar
  • 39 Julian C G, Woodruff D. The biologic behavior of low-grade papillary serous carcinoma of the ovary.  Obstet Gynecol. 1972;  40 860-867
    PubMedGoogle Scholar
  • 40 Maneo A, Vignali M, Chiari S et al. Are borderline tumors of the ovary safely treated by laparoscopy?.  Gynecol Oncol. 2004;  94 387-392
    CrossrefPubMedGoogle Scholar
  • 41 Boran N, Cil A P, Tulunay G et al. Fertility and recurrence results of conservative surgery for borderline ovarian tumors.  Gynecol Oncol. 2005;  97 845-851
    CrossrefPubMedGoogle Scholar
  • 42 Guerrieri C, Hogberg T, Wingren S et al. Mucinous borderline and malignant tumors of the ovary.  Cancer. 1994;  74 2329-2340
    CrossrefPubMedGoogle Scholar
  • 43 McKenney J K, Balzer B L, Longacre T A. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): A reevaluation of the concept of stromal microinvasion.  Am J Surg Path. 2006;  30 1209-1221
    CrossrefPubMedGoogle Scholar
  • 44 Pirimoglu Z M, Afsin Y, Guzelmeric K, Yilmaz M et al. Is it necessary to do retroperitoneal evaluation in borderline epithelial ovarian tumors.  Arch Gynecol Obstet. 2008;  277 411-414
    CrossrefPubMedGoogle Scholar
  • 45 Smith Sehdev A E, Sehdev P S, Kurman R J. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary. A clinicopathologic analysis of 135 cases.  Am J Surg Pathol. 2003;  27 725-736
    CrossrefPubMedGoogle Scholar
  • 46 Allison K H, Swisher E M, Kerkering K M et al. Defining an appropriate threshold for the diagnosis of serous borderline tumor of the ovary: When is a full staging procedure unnecessary?.  Int J Gynecol Path. 2007;  27 10-17
    PubMedGoogle Scholar
  • 47 Katzenstein A L A, Mazur M T, Morgan T E et al. Proliferative serous tumors of the ovary.  Am J Surg Pathol. 1978;  5 339-355
    PubMedGoogle Scholar
  • 48 Bristow R E, Gossett D R, Shook D R et al. Micropapillary serous ovarian carcinoma: Surgical management and clinical outcome.  Gynecol Oncol. 2002;  86 163-170
    CrossrefPubMedGoogle Scholar
  • 49 Fort M G, Pierce V K, Saigo P E et al. Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential.  Gynecol Oncol. 1989;  32 269-272
    CrossrefPubMedGoogle Scholar
  • 50 Hogg R, Scurry J, Kim S-N et al. Microinvasion links ovarian serous borderline tumor and grade I invasive carcinoma.  Gynecol Oncol. 2007;  106 44-51
    CrossrefPubMedGoogle Scholar
  • 51 Engelen M J A, de Bruijn H W A, Hollema H et al. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.  Gynecol Oncol. 2000;  78 16-20
    CrossrefPubMedGoogle Scholar
  • 52 Morris R T, Gershenson D M, Silva E G et al. Outcome and reproductive function after conservative surgery for borderline ovarian tumors.  Obstet Gynecol. 2000;  95 541-547
    CrossrefPubMedGoogle Scholar
  • 53 Camatte S, Morice P, Atallah D et al. Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: An analysis of a series of 42 lymphadenectomies.  J Am Coll Surg. 2002;  195 332-338
    CrossrefPubMedGoogle Scholar
  • 54 Casey A C, Bell D A, Lage J M et al. Epithelial ovarian tumors of borderline malignancy: Long-term follow-up.  Gynecol Oncol. 1993;  50 316-322
    CrossrefPubMedGoogle Scholar
  • 55 Rao G G, Skinner E N, Gehring P A et al. Fertility-sparing surgergy for ovarian low malignant potential tumors.  Gynecol Onkol. 2005;  98 263-266
    CrossrefPubMedGoogle Scholar
  • 56 Betash N, Modares M, Abolhasani M et al. Borderline ovarian tumours: clinical analysis of 38 cases.  J Obstet Gynaecol. 2004;  24 157-160
    CrossrefPubMedGoogle Scholar
  • 57 Lim-Tan S K, Cajigas H E, Sculy R E. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases.  Obstet Gynecol. 1988;  72 775-781
    PubMedGoogle Scholar
  • 58 Leake J F, Rader J S, Woodruff J D et al. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential.  Gynecol Oncol. 1991;  42 124-130
    CrossrefPubMedGoogle Scholar
  • 59 Massad L S, Hunter V J, Szpak C A et al. Epithelial ovarian tumors of low malignant potential.  Obstet Gynecol. 1991;  78 1027-1031
    PubMedGoogle Scholar
  • 60 Demeter A, Csapó Z, Szánthó A et al. A retrospective study of 27 ovarian tumors of low malignant potential.  Eur J Gynaecol Oncol. 2002;  23 415-418
    PubMedGoogle Scholar
  • 61 Darai E, Teboul J, Fauconnier A et al. Management and outcome of borderline ovarian tumors incidentally discovered at or after laparoscopy.  Acta Obstet Gynecol Scand. 1998;  77 451-457
    CrossrefPubMedGoogle Scholar
  • 62 Chan J K, Lin Y G, Loizzi V et al. Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome.  J Reprod Med. 2003;  48 756-760
    PubMedGoogle Scholar
  • 63 Laurent I, Uzan C, Gouy S et al. Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern.  Ann Surg Oncol. 2008;  15 3561-3566
    CrossrefPubMedGoogle Scholar
  • 64 Shappell H W, Riopel M A, Smith Sehdev A E et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors.  Am J Surg Path. 2002;  26 1529-1541
    CrossrefPubMedGoogle Scholar
  • 65 O'Quinn A G, Hannigan E V. Epithelial ovarian neoplasms of low malignant potential.  Gynecol Oncol. 1985;  21 177-185
    CrossrefPubMedGoogle Scholar
  • 66 Nezhat F R, Ezzati M, Chuang L et al. Laparoscopic management of early ovarian and fallopian tube cancers: surgical and survival outcome.  Am J Obstet Gynecol. 2009;  200 83.e1-83.e6
    PubMedGoogle Scholar
  • 67 Morice P, Camatte S, Rey A et al. Prognostic factors for patients with advanced stage serous borderline tumors of the ovary.  Ann Oncol. 2003;  14 592-598
    CrossrefPubMedGoogle Scholar
  • 68 Silva E G, Gershenson D M, Malpica A et al. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.  Am J Surg Pathol. 2006;  30 1367-1371
    CrossrefPubMedGoogle Scholar
  • 69 Gershenson D M, Silva E G, Tortolero-Luna G et al. Serous borderline tumors of ovarian with noninvasive peritoneal implants.  Cancer. 1998;  83 2157-2163
    CrossrefPubMedGoogle Scholar
  • 70 Bell D A, Weinstock M A, Scully R E. Peritoneal implants of ovarian serous borderline tumors.  Cancer. 1988;  62 2212-2222
    CrossrefPubMedGoogle Scholar
  • 71 Gershenson D M, Silva E G, Levy L et al. Ovarian serous borderline tumors with invasive peritoneal implants.  Cancer. 1998;  82 1096-1103
    CrossrefPubMedGoogle Scholar
  • 72 Barakat R R, Benjamin I, Lewis Jr. J L et al. Platinum-based chemotherapy for advanced-stage ovarian carcinoma malignant potential.  Gynecol Oncol. 1995;  59 390-393
    CrossrefPubMedGoogle Scholar
  • 73 Camatte S, Morice P, Pautier P et al. Fertility results after conservative treatment of advanced stage serous borderline tumor of the ovary.  BJOG. 2002;  109 376-380
    PubMedGoogle Scholar
  • 74 Lackmann F, Carey M S, Kirk M E et al. Surgery as sole treatment for serous borderline tumors of the ovary with noninvasive implants.  Gynecol Oncol. 2003;  90 407-412
    CrossrefPubMedGoogle Scholar
  • 75 Vandeput I, Amant F, Vergote I. Peritoneal recurrences might be less common in advanced stage serous borderline ovarian tumors that were treated by laparotomy.  Gynecol Oncol. 2005;  98 523 , (letter)
    CrossrefPubMedGoogle Scholar
  • 76 Deffieux X, Morice P, Camatte S et al. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants.  Gynecol Oncol. 2005;  97 84-89
    CrossrefPubMedGoogle Scholar
  • 77 Nijman H W, Burger C W, Baak J P A et al. Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases.  Eur J Cancer. 1992;  28 A 1971-1973
    PubMedGoogle Scholar
  • 78 Barnhill D R, Kurman R J, Brady M F et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: A Gynecologic Oncology Group Study.  J Clin Oncol. 1995;  13 2752-2756
    PubMedGoogle Scholar
  • 79 Desfeux P, Camatte S, Chatellier G et al. Impact of surgical approach on the management of macroscopic early ovarian borderline tumors.  Gynecol Oncol. 2005;  98 390-395
    CrossrefPubMedGoogle Scholar
  • 80 Odegaard E, Staff A C, Langebrekke A et al. Surgery of borderline tumors of the ovary; retrospective comparison of short-term outcome after laparoscopy or laparotomy.  Acta Obstet Gynecol. 2007;  86 620-626
    CrossrefPubMedGoogle Scholar
  • 81 Camatte S, Morice P, Thoury A et al. Impact of surgical staging in patients with macroscopic “stage I” ovarian borderline tumours: analysis of a continuous series of 101 cases.  Eur J Cancer. 2004;  40 1842-1849
    CrossrefPubMedGoogle Scholar
  • 82 Ji H, Yliskoski M, Anttila M et al. Management of stage-I borderline ovarian tumors.  Int J Gynecol Oncol. 1996;  54 37-44
    PubMedGoogle Scholar
  • 83 Tazelaar H D, Bostwick D G, Ballon S C et al. Conservative treatment of borderline ovarian tumors.  Obstet Gynecol. 1985;  66 417-422
    PubMedGoogle Scholar
  • 84 Creasman W T, Park R, Norris H et al. Stage I borderline ovarian tumors.  Obstet Gynecol. 1982;  59 93-96
    PubMedGoogle Scholar
  • 85 Tinelli F G, Tinelli R, La Grotta F et al. Pregnancy outcome and recurrence after conservative laparoscopic surgery for borderline ovarian tumors.  Acta Obstet Gynecol. 2007;  86 81-87
    CrossrefPubMedGoogle Scholar
  • 86 Marcickiewicz J, Brannstrom M. Fertility preserving surgical treatment of borderline ovarian tumour: long-term consequence for fertility and recurrence.  Acta Obstet Gynecol. 2006;  85 1496-1500
    CrossrefPubMedGoogle Scholar
  • 87 Seracchioli R, Venturoli S, Colombo F M et al. Fertility and tumor recurrence rate after conservative laparoscopic management of young women with early-stage borderline ovarian tumors.  Fertil Steril. 2001;  76 999-1004
    CrossrefPubMedGoogle Scholar
  • 88 Fasouliotis S J, Davis O, Schattman G et al. Safety and efficacy of infertility treatment after conservative management of borderline ovarian tumors: a preliminary report.  Fertil Steril. 2004;  82 568-572
    CrossrefPubMedGoogle Scholar
  • 89 Skirnisdottir I, Garmo H, Wilander E et al. Borderline ovarian tumors in Sweden 1960–2005: Trends in incidence and age at diagnosis compared to ovarian cancer.  Int J Cancer. 2008;  123 1897-1901
    CrossrefPubMedGoogle Scholar
  • 90 Iscovich J, Shushan A, Schenker J G et al. The incidence of borderline ovarian tumors in Israel. A population-based study.  Cancer. 1998;  82 147-151
    CrossrefPubMedGoogle Scholar
  • 91 Levi F, La Vecchia C, Randimbison L et al. Borderline ovarian tumors in Vaud, Switzerland: Incidence, survival and second neoplasms.  Br J Cancer. 1999;  79 4-6
    CrossrefPubMedGoogle Scholar
  • 92 Mink P J, Sherman M E, Devesa S S. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States: Results from the SEER program, 1978–1998.  Cancer. 2002;  95 2380-2389
    CrossrefPubMedGoogle Scholar
  • 93 Heintz A P M, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. Pecorelli S 26th annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 2006 95 (Suppl. 1): 161-192
    PubMedGoogle Scholar
  • 94 Pal T, Permuth-Wey J, Betts J A et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.  Cancer. 2005;  104 2807-2816
    CrossrefPubMedGoogle Scholar
  • 95 Gotlieb W H, Chetrit A, Menczer J et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer.  Gynecol Oncol. 2005;  97 780-783
    CrossrefPubMedGoogle Scholar
  • 96 Gram I T, Braaten T, Adami H-O et al. Cigarette smoking and risk of borderline and invasive epithelial ovarian cancer.  Int J Cancer. 2008;  122 647-652
    CrossrefPubMedGoogle Scholar
  • 97 Jordan S J, Green A C, Whiteman D C for the Australian Cancer Study (Ovarian Cancer), and the Australian Ovarian Cancer Study Group et al. Risk factors for benign, borderline and invasive mucinous ovarian tumors: Epidemiological evidence of a neoplastic continuum.  Gynecol Oncol. 2007;  107 223-230
    CrossrefPubMedGoogle Scholar
  • 98 Collaborative Group of Epidemiological Studies of Ovarian Cancer . Ovarian cancer and oral contraceptives; collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87303 controls.  Lancet. 2008;  371 303-314
    CrossrefPubMedGoogle Scholar
  • 99 Ness R B, Cramer D W, Goodmann M T et al. Infertility, fertility drugs, and ovarian cancer: A pooled analysis of case-control studies.  Am J Epidemiol. 2002;  155 217-224
    CrossrefPubMedGoogle Scholar
  • 100 Zreik T G, Ayoub C M, Hannoun A et al. Fertility drugs and risk of ovarian cancer: Dispelling the myth.  Curr Opin Obstst Gynecol. 2008;  20 313-319
    PubMedGoogle Scholar
  • 101 Rossing M A, Tang M T C, Flagg E W et al. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs.  Am J Epidemiol. 2004;  160 1070-1078
    CrossrefPubMedGoogle Scholar
  • 102 Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor. A review.  Placenta. 2008;  29 S169-S177
    CrossrefPubMedGoogle Scholar
  • 103 Parazzini F, Negri E, La Vecchia C et al. Treatment for fertility and risk of ovarian tumors of borderline malignancy.  Gynecol Oncol. 1998;  68 226-228
    CrossrefPubMedGoogle Scholar
  • 104 Rossing M A, Daling J R, Weiss N S et al. Ovarian tumors in a cohort of infertile women.  N Engl J Med. 1994;  331 771-776
    CrossrefPubMedGoogle Scholar
  • 105 Jensen A, Sharif H, Frederiksen K et al. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study.  BMJ. 2009;  338 b249 DOI: 10.1136/bmj.b249
    CrossrefPubMedGoogle Scholar
  • 106 Venn A, Watson L, Bruinsma F et al. Risk of cancer after use of fertility drugs with in-vitro fertilization.  Lancet. 1999;  354 1586-1590
    CrossrefPubMedGoogle Scholar
  • 107 Landen Jr. C N, Birrer M J, Sood A K. Early events in the pathogenesis of epithelial ovarian cancer.  J Clin Oncol. 2008;  26 995-1005
    CrossrefPubMedGoogle Scholar
  • 108 Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact.  J Clin Oncol. 2008;  26 1-10
    CrossrefPubMedGoogle Scholar
  • 109 Kurman R J, Visvanathan K, Roden R et al. Early detection and treatment of ovarian cancer: Shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.  Am J Obstet Gynecol. 2008;  198 351-356
    CrossrefPubMedGoogle Scholar
  • 110 Kurman R J, Shih I-M. Pathogenesis of ovarian cancer: Lessons from morphology and molecular biology and their clinical implications.  Int J Gynecol Pathol. 2008;  27 151-160
    PubMedGoogle Scholar
  • 111 Olsen C M, Green A C, Nagle C M et al. Epithelial ovarian cancer: testing the “androgen hypothesis”.  Endocrine-Related Cancer. 2008;  15 1061-1068
    PubMedGoogle Scholar
  • 112 Berchuck A, Heron K A, Carney M E et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer.  Clin Cancer Res. 1998;  4 2433-2437
    PubMedGoogle Scholar
  • 113 Merajver S D, Pham T M, Caduff R F et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumors.  Nat Genet. 1995;  9 439-443
    CrossrefPubMedGoogle Scholar
  • 114 Thrall M, Gallion H H, Kryscio R et al. BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study.  Int J Gynecol Cancer. 2006;  16 166-171
    CrossrefPubMedGoogle Scholar
  • 115 Zheng W, Luo F, Lu J J et al. Reduction of BRCA1 expression in sporadic ovarian cancer.  Gynecol Oncol. 2000;  76 294-300
    CrossrefPubMedGoogle Scholar
  • 116 Russel P A, Pharoah P D, De Foy K et al. Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers.  Int J Cancer. 2000;  87 317-321
    CrossrefPubMedGoogle Scholar
  • 117 Wang C. Expression of BRCA1 protein in benign borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.  J Pathol. 2004;  202 215-223
    CrossrefPubMedGoogle Scholar
  • 118 Plaxe S C. Epidemiology of low-grade serous ovarian cancer.  Am J Obstet Gynecol. 2008;  198 459.e1-459.e9
    PubMedGoogle Scholar
  • 119 Meinhold-Heerlein I, Bauerschlag D, Hilpert F et al. Molecular and prognostic distinction between serous ovarian carcinoma of varying grade and malignant potential.  Oncogene. 2005;  24 1053-1065
    CrossrefPubMedGoogle Scholar
  • 120 Bonome T, Lee J Y, Park D C et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.  Cancer Res. 2005;  65 10602-10612
    CrossrefPubMedGoogle Scholar
  • 121 Gershenson D M, Wong K K. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary. Educational Book.  Am Soc Clinical Oncol. 2007;  313-317
    PubMedGoogle Scholar
  • 122 Piek J M, van Diest P J, Zweemer R P et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer.  J Pathol. 2001;  195 451-456
    CrossrefPubMedGoogle Scholar
  • 123 Lee Y, Miron A, Drapkin R et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube.  J Pathol. 2007;  211 26-35
    CrossrefPubMedGoogle Scholar
  • 124 Jarboe E, Folkins A, Nucci M R et al. Serous carcinogenesis in the fallopian tube: A descriptive classification.  Int J Gynecol Pathol. 2008;  27 1-9
    CrossrefPubMedGoogle Scholar
  • 125 Palomba S, Zupi E, Russo T et al. Comparison of two fertility-sparing approaches for bilateral borderline tumours: a randomized controlled study.  Human Rep. 2007;  22 578-585
    PubMedGoogle Scholar
  • 126 Chang S-J, Ryu H-S, Chang K-H et al. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.  Acta Obstet Gynecol. 2008;  87 478-481
    PubMedGoogle Scholar
  • 127 Kaern J, Trope C G, Kristensen G B et al. DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary.  Int J Gynecol Cancer. 1993;  3 349-358
    CrossrefPubMedGoogle Scholar
  • 128 Lai C-H, Hsueh S, Chang T-C et al. The role of DNA flow cytometry in borderline malignant ovarian tumors.  Cancer. 1996;  78 794-802
    CrossrefPubMedGoogle Scholar
  • 129 Meyer J S, Gersell D J, Yim S Y. Cell proliferation in ovarian carcinoma: Superior accuracy of S-phase fraction (SPF) by DNA labelling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.  Gynecol Oncol. 2001;  81 466-476
    CrossrefPubMedGoogle Scholar
  • 130 Verbruggen M B, van Diest P J, Baak J P et al. The prognostic and clinical value of morphometric and DNA cytometry in borderline ovarian tumors: a prospective study.  Int J Gynecol Pathol. 2009;  28 35-40
    CrossrefPubMedGoogle Scholar
  • 131 Snider D D, Stuart G C E, Nation J G et al. Evaluation of surgical staging in stage I low malignant potential ovarian tumors.  Gynecol Oncol. 1991;  40 129-132
    CrossrefPubMedGoogle Scholar
  • 132 Fortin A, Morice P, Thoury A et al. Impact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenter study.  Fertil Steril. 2007;  87 591-596
    CrossrefPubMedGoogle Scholar
  • 133 Brun J-L, Cortez A, Rouzier R et al. Factors influencing the use and accuracy of frozen section diagnosis of epithelial ovarian tumors.  Am J Obstet Gynecol. 2006;  199 244.e1-244.e7
    PubMedGoogle Scholar
  • 134 Attanucci C A, Ball H G, Zweizig S L et al. Differences in symptoms between patients with benign and malignant ovarian neoplasms.  Am J Obstet Gynecol. 2004;  190 1435-1437
    CrossrefPubMedGoogle Scholar
  • 135 Vine M F, Calingaert B, Berchuck A et al. Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls.  Gynecol Oncol. 2003;  90 75-82
    CrossrefPubMedGoogle Scholar
  • 136 Vine M, Ness R B, Calingaert B et al. Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor.  Gynecol Oncol. 2001;  83 466-471
    CrossrefPubMedGoogle Scholar
  • 137 Webb P M, Purdie D M, Grover S et al. Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer.  Gynecol Oncol. 2004;  92 232-239
    CrossrefPubMedGoogle Scholar
  • 138 Economou A, Panagopoulos P, Koutras I et al. A retrospective study of 32 borderline ovarian tumors: The experience of a non-specialized centre.  Eur J Gynaecol Oncol. 2005;  26 196-198
    PubMedGoogle Scholar
  • 139 DeSouza N M, O'Neill R, McIndoe G A et al. Borderline tumors of the ovary: CT and MRI features and tumor markers in differentiation from stage I disease.  AJR. 2005;  184 999-1003
    PubMedGoogle Scholar
  • 140 Yazigi R, Sandstad J, Munoz A K. Primary staging in ovarian tumors of low malignant potential.  Gynecol Oncol. 1988;  31 402-408
    CrossrefPubMedGoogle Scholar
  • 141 Nikrui N. Survey of clinical behavior of patients with borderline epithelial tumors of the ovary.  Gynecol Oncol. 1981;  12 107-119
    CrossrefPubMedGoogle Scholar
  • 142 Eltabbakh G H, Yadev P R, Morgan A. Clinical picture of women with early stage ovarian cancer.  Gynecol Oncol. 1999;  75 476-479
    CrossrefPubMedGoogle Scholar
  • 143 Sykes P H, Quinn M A, Rome R M. Ovarian tumors of low malignant potential: A retrospective study of 234 patients.  Int Gynecol Cancer. 1997;  7 218-226
    PubMedGoogle Scholar
  • 144 Tamakoshi K, Kikkawa F, Shibata K et al. Clinical value of CA 125, CA 19-9, CEA, CA 72-4 and TPA in borderline ovarian tumor.  Gynecol Oncol. 1996;  62 67-72
    CrossrefPubMedGoogle Scholar
  • 145 Schutter E M- J, Davelaar E M, van Kamp G J et al. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass.  Am J Obstet Gynecol. 2002;  187 385-392
    CrossrefPubMedGoogle Scholar
  • 146 Gotlieb W H, Soriano D, Achiron R et al. CA 125 measurement and ultrasonography in borderline tumors of the ovary.  Am J Obstet Gynecol. 2000;  183 541-546
    CrossrefPubMedGoogle Scholar
  • 147 Benedet J L, Bender H, Jones III H et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology.  Int J Gynaecol Obstet. 2000;  70 209-262
    CrossrefPubMedGoogle Scholar
  • 148 du Bois A, Burges A, Emons G et al. In: Schmalfeldt B, Pfisterer J, Hrsg. Interdisziplinäre S2 k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren 2007, Kommission Ovar der AGO e. V. München; W. Zuckschwerdt Verlag 2007
    PubMedGoogle Scholar
  • 149 Cadron I, Leunen K, van Gorp T et al. Management of borderline neoplasms.  J Clin Oncol. 2007;  25 2928-2937
    CrossrefPubMedGoogle Scholar
  • 150 Verleye L, Ottevanger P B, Graaf W et al. EORTC-GCG process quality indicators for ovarian cancer surgery. Gynaecological Cancer Group (GCG) of European Organisation for Research and Treatment of Cancer (EORTC).  Eur J Cancer. 2009;  45 517-526
    CrossrefPubMedGoogle Scholar
  • 151 du Bois A, Rochon J, Pfisterer J et al. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: A systematic review.  Gynecol Oncol. 2008;  112 422-436
    CrossrefPubMedGoogle Scholar
  • 152 Lin P S, Gershenson D M, Bevers M W et al. The current status of surgical staging of ovarian serous borderline tumors.  Cancer. 1999;  85 905-911
    CrossrefPubMedGoogle Scholar
  • 153 Menzin A W, Gal D, Lovecchio J L. Contemporary surgical management of borderline ovarian tumors: A survey of the society of gynecologic oncologists.  Gynecol Oncol. 2000;  78 7-9
    CrossrefPubMedGoogle Scholar
  • 154 Olsen C M, Green A C, Nagle C M et al. Epithelial ovarian cancer: testing the “androgen hypothesis”.  Endocrine-Related Cancer. 2008;  15 1061-1068
    PubMedGoogle Scholar
  • 155 Di Re F, Paladini D, Fontanelli R et al. Surgical staging for epithelial ovarian tumors of low malignant potential.  Int J Gynecol Cancer. 1994;  4 310-314
    CrossrefPubMedGoogle Scholar
  • 156 McKenney J K, Balzer J K, Longacre T A. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors).  Am J Surg Path. 2006;  30 614-624
    CrossrefPubMedGoogle Scholar
  • 157 Wingo S N, Knowles L M, Carrick K S et al. Retrospective cohort study of surgical staging for ovarian low malignant potential tumors.  Am J Obstet Gynecol. 2006;  194 20-22
    CrossrefPubMedGoogle Scholar
  • 158 Tempfer C B, Polterauer S, Bentz E-K et al. Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: A retrospective analysis of 96 cases and review of the literature.  Gynecol Oncol. 2007;  107 248-252
    CrossrefPubMedGoogle Scholar
  • 159 Wasinghon P, Suthhippintawong C, Tuipae S. The accuracy of intraoperative frozen sections in the diagnosis of ovarian tumors.  J Med Assoc Thai. 2008;  91 1791-1795
    PubMedGoogle Scholar
  • 160 Rakhshan A, Zham H, Kazempour M. Accuracy of frozen section diagnosis in ovarian masses: experience at a tertiary oncology center.  Arch Gynecol Obstet. 2008;  DOI: 10.1007/s00404-008-0899-6
    PubMedGoogle Scholar
  • 161 Yarandi F, Eftekhar Z, Izadi-Mod N et al. Accuracy of intraoperative frozen section in the diagnosis of ovarian tumors.  Aus NZ J Obstet Gynecol. 2008;  48 438-441
    PubMedGoogle Scholar
  • 162 Twaalfhoven F C M, Peters A A W, Trimbos J B et al. The accuracy of frozen section diagnosis of ovarian tumors.  Gynecol Oncol. 1991;  41 189-192
    CrossrefPubMedGoogle Scholar
  • 163 Rose P G, Rubin R B, Nelson B E et al. Accuracy of frozen-section (intraoperative consultation) diagnosis of ovarian tumors.  Am J Obstet Gynecol. 1994;  171 823-826
    PubMedGoogle Scholar
  • 164 Yeo E L, Yu K M, Poddar N C et al. The accuracy of intraoperative frozen section in the diagnosis of ovarian tumors.  J Obstet Gynaecol Res. 1998;  24 189-195
    CrossrefPubMedGoogle Scholar
  • 165 Pinto P B C, Andrade A L A, Derchain S F M. Accuracy of intraoperative frozen section diagnosis of ovarian tumors.  Gynecol Oncol. 2001;  81 230-232
    CrossrefPubMedGoogle Scholar
  • 166 Trimbos J B, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.  J Natl Cancer Inst. 2003;  95 113-125
    CrossrefPubMedGoogle Scholar
  • 167 Zanetta G, Rota S, Chiari S et al. The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma.  Ann Oncol. 1998;  9 1097-1101
    CrossrefPubMedGoogle Scholar
  • 168 Torrent Colomer A, Martin Jiminez A, Bover Barcelo M I. Laparoscopic treatment and staging of early ovarian cancer.  J Minimal Inv Gyn. 2008;  15 414-419
    PubMedGoogle Scholar
  • 169 Hopkins M P, Morley G W. The second-look operation and surgical reexploration in ovarian tumor of low malignant potential.  Obstet Gynecol. 1989;  74 375-378
    PubMedGoogle Scholar
  • 170 Darai E, Tulpin L, Prugnolle H et al. Laparoscopic restaging of borderline ovarian tumors.  Surg Endosc. 2007;  21 2039-2043
    CrossrefPubMedGoogle Scholar
  • 171 Fauvet R, Boccara J, Dufournet C et al. Restaging surgery for women with borderline ovarian tumors.  Cancer. 2004;  100 1145-1151
    CrossrefPubMedGoogle Scholar
  • 172 Querleu D, Papageorgiou T, Lambaudie E et al. Laparoscopic restaging of borderline ovarian tumours: results of 30 cases initially presumed as stage IA borderline ovarian tumours.  BJOG. 2003;  110 201-204
    PubMedGoogle Scholar
  • 173 Gershenson D M. Clinical management potential tumors of low malignancy.  Best Pract Res Clin Obstet Gynecol. 2002;  16/4 513-527
    PubMedGoogle Scholar
  • 174 Kurman R J, Trimble C L. The behavior of serous tumors of low malignant potential: Are they ever malignant?.  Inter J Gynecol Pathol. 1993;  12 120-127
    PubMedGoogle Scholar
  • 175 Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.  Gynecol Oncol. 2006;  103 841-847
    CrossrefPubMedGoogle Scholar
  • 176 Poncelet C, Fauvet R, Boccara J et al. Recurrence after cystectomy for borderline ovarian tumors: Results of a French multicenter study.  Ann Surg Oncol. 2006;  13 565-571
    CrossrefPubMedGoogle Scholar
  • 177 Yinon Y, Beiner M E, Gotlieb W H et al. Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline tumors.  Fertil Steril. 2007;  88 479-484
    CrossrefPubMedGoogle Scholar
  • 178 Fauvet R, Poncelet C, Boccara J et al. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study.  Fertil Steril. 2005;  83 284-290
    CrossrefPubMedGoogle Scholar
  • 179 Kehoe S, Powell J. Long-term follow-up of women with borderline ovarian tumors.  Int J Gynaecol Obstet. 1996;  53 139-143
    CrossrefPubMedGoogle Scholar
  • 180 Beiner M E, Gotlieb W H, Davidson B et al. Infertility treatment after conservative management of borderline ovarian tumors.  Cancer. 2001;  92 320-325
    CrossrefPubMedGoogle Scholar
  • 181 Borgfeldt C, Iosif C, Masbaeck A. Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer.  Eur J Obstet Gynecol Rep Biol. 2007;  134 110-114
    PubMedGoogle Scholar
  • 182 Salomon L J, Lhomme C, Pautier P et al. Safety of simple cystectomy in patients with unilateral mucinous borderline tumors.  Fertil Steril. 2006;  85 1510.e1-4
    PubMedGoogle Scholar
  • 183 Morice P. Borderline tumours of the ovary and fertility.  Eur J Cancer. 2006;  42 149-158
    CrossrefPubMedGoogle Scholar
  • 184 du Bois A, Reuss A, Pujade-Lauraine E et al. The role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. A combined exploratory analysis of three prospectively randomized phase III multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux pour les Etudes des Cancers de l'Ovaire (GINECO).  Cancer. 2009;  115 1234-1244
    CrossrefPubMedGoogle Scholar
  • 185 Winter III W E, Maywell G L, Tian C et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: A Gynecologic Oncology Group study.  J Clin Oncol. 2008;  26 83-89
    CrossrefPubMedGoogle Scholar
  • 186 Winter III W E, Maxwell G L, Tian C T et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study.  J Clin Oncol. 2007;  25 3621-3627
    CrossrefPubMedGoogle Scholar
  • 187 Tinelli R, Tineli A, Tinelli F G et al. Conservative surgery for borderline ovarian tumors: A review.  Gynecol Oncol. 2006;  100 185-191
    CrossrefPubMedGoogle Scholar
  • 188 Park J-Y, Bae J, Lim M C et al. Laparoscopic and laparotomic staging in stage I epithelial ovarian cancer: a comparison of feasibility and safety.  Int J Gynecol Oncol. 2008;  18 1202-1209
    CrossrefPubMedGoogle Scholar
  • 189 Obermair A, Hiebl S. Laparoscopy in the treatment of ovarian tumours of low malignant potential.  Aust NZ J Obstet Gynaecol. 2007;  47 438-444
    CrossrefPubMedGoogle Scholar
  • 190 Zivanovic O, Sonoda Y, Diaz J P et al. The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease.  Gynecol Oncol. 2008;  111 431-437
    CrossrefPubMedGoogle Scholar
  • 191 Ramirez P T, Frumovitz M, Wolf J K et al. Laparoscopic port-site metastases in patients with gynecological malignancies.  Int J Gynecol Cancer. 2004;  14 1070-1077
    CrossrefPubMedGoogle Scholar
  • 192 Vergote I, Marquette S, Amant F et al. Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma.  Int J Gynecol Cancer. 2005;  15 776-779
    CrossrefPubMedGoogle Scholar
  • 193 Huang K-G, Wang C-J, Chang T-C et al. Management of port-site metastasis after laparoscopic surgery for ovarian cancer.  Obstet Gynecol. 2003;  189 16-21
    PubMedGoogle Scholar
  • 194 Morice P, Camatte S, Larregain-Fournier D et al. Port-site implantation after laparoscopic treatment of borderline ovarian tumors.  Obstet Gynecol. 2004;  104 1167-1170
    PubMedGoogle Scholar
  • 195 Havrilesky L J, Peterson B L, Dryden D K et al. Predictors of clinical outcomes in the laparoscopic management of adnexal masses.  Obstet Gynecol. 2003;  102 243-251
    CrossrefPubMedGoogle Scholar
  • 196 Sainz de la Cuesta R S, Goff B A, Fuller A F et al. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms.  Obstet Gynecol. 1994;  84 1-7
    PubMedGoogle Scholar
  • 197 Vergote I, De Brabanter J, Fyles A et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.  Lancet. 2001;  375 176-182
    PubMedGoogle Scholar
  • 198 Medeiros L R, Stein A T, Fachel J et al. Laparoscopy versus laparotomy for benign ovarian tumor: a systematic review and metaanalysis.  Int J Gynecol Cancer. 2008;  18 387-399
    CrossrefPubMedGoogle Scholar
  • 199 Brown Jones M. Borderline ovarian tumors: Current concepts for prognostic factors and clinical management.  Clin Obstet Gynecol. 2006;  49 517-525
    CrossrefPubMedGoogle Scholar
  • 200 Barnhill D, Heller P, Brzozowski P et al. Epithelial ovarian carcinoma of low malignant potential.  Obstet Gynecol. 1985;  65 53-59
    PubMedGoogle Scholar
  • 201 Swanton A, Bankhead C R, Kehoe S. Pregnancy rates after conservative treatment for borderline ovarian tumours: A systematic review.  Eur J Obstet Gynecol. 2007;  135 3-7
    CrossrefPubMedGoogle Scholar
  • 202 Attar E, Berkman S, Topuz S et al. Evolutive peritoneal disease after conservative management and the use of infertility drugs in a patient with stage IIIC borderline micro-papillary serous carcinoma (MPSC) of the ovary: Case report.  Human Reproduction. 2004;  19 1472-1475
    CrossrefPubMedGoogle Scholar
  • 203 Hoffman J S, Laird L, Benadiva C et al. Case Report: In vitro fertilization following conservative management of stage 3 serous borderline tumor of the ovary.  Gynecol Oncol. 1999;  74 515-518
    CrossrefPubMedGoogle Scholar
  • 204 Mantzavinos T, Kanakas N, Genatas C et al. Five years' follow-up in the two patients with borderline tumours of the ovary hyperstimulated by gonadotrophin therapy for in-vitro fertilization.  Human Reproduction. 1994;  9 2032-2033
    PubMedGoogle Scholar
  • 205 Jeruss J S, Woodruff T K. Preservation of fertility in patients with cancer.  N Engl J Med. 2009;  360 902-911
    CrossrefPubMedGoogle Scholar
  • 206 Fain-Kahn V, Poirot C, Uzan C et al. Feasibility of ovarian cryopreservation in borderline ovarian tumours.  Hum Reprod. 2009;  1 1-6
    PubMedGoogle Scholar
  • 207 Crispens M A. Borderline ovarian tumours: a review of the recent literature.  Cur Opin Obstet Gynecol. 2003;  15 39-48
    PubMedGoogle Scholar
  • 208 Ortiz B H, Ailawadi M, Colitti C et al. Second primary or recurrence? Comparative patterns of p 53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.  Cancer Res. 2001;  61 7264-7267
    PubMedGoogle Scholar
  • 209 Emerson R E, Wang M, Liu F et al. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.  Int J Gynecol Pathol. 2007;  26 387-394
    CrossrefPubMedGoogle Scholar
  • 210 Gu J, Roth L M, Younger C et al. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential.  J Natl Cancer Inst. 2001;  93 1147-1152
    CrossrefPubMedGoogle Scholar
  • 211 Bouchardy C, Fernandez S, Merglen A et al. Increased risk of second cancer among patients with ovarian borderline tumors.  Gynecol Oncol. 2008;  109 210-214
    CrossrefPubMedGoogle Scholar
  • 212 Crispens M A, Bodurka D, Deavers M et al. Response and survival in patients with progressive or recurrent serous tumors of low malignant potential.  Obstet Gynecol. 2002;  99 3-10
    CrossrefPubMedGoogle Scholar
  • 213 Genadry R, Poliakoff S, Rotmensch J et al. Primary, papillary peritoneal neoplasia.  Obstet Gynecol. 1981;  58 730-734
    PubMedGoogle Scholar
  • 214 Russel P, Merkur H. Proliferating ovarian “epithelial” tumours: A clinico-pathological analysis of 144 cases.  Aust N Z J Obstet Gynaec. 1979;  19 45-51
    CrossrefPubMedGoogle Scholar
  • 215 Schmeler K M, Gershenson D M. Low-grade serous ovarian cancer: a unique disease.  Curr Oncol Rep. 2008;  10 519-523
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. Andreas du Bois

Klinikdirektor
Klinik für Gynäkologie & gynäkologische Onkologie
Dr. Horst Schmidt Klinik (HSK)

Ludwig-Erhard-Straße 100

65199 Wiesbaden

Email: prof.dubois@googlemail.com

      >